|Bid||5.58 x 2900|
|Ask||5.59 x 2200|
|Day's Range||5.56 - 5.79|
|52 Week Range||4.08 - 11.10|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.96|
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission ("SEC"), under which it may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $75,000,000 million through an "at-the-market" equity offering program (the "ATM Program"). The timing and amount of any sales will be determined by a variety of factors considered by Clovis Oncology.
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So take a...
Clovis (CLVS) reports lower-than-expected loss for first-quarter 2021. Lower new patient start amid COVID-19 hurts U.S. sales of Rubraca. Stock up.